Plain-English translation of NCT06428409 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
Researchers are testing whether a new drug called can help treat advanced gastrointestinal cancers — including colorectal cancer, pancreatic cancer, and bile duct cancer — that have either spread to other parts of the body or cannot be surgically removed. The study will test this medication alone and in combination with other existing cancer treatments to see if it is safe and how well it works. About 220 people will participate in this phase 1/2 trial.
Current treatments for advanced gastrointestinal cancers don't work well enough for all patients, and doctors need new options. This medication is designed to target cancer cells in a new way, and researchers want to find out if it could offer another hope for people with these difficult-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly to receive your assigned medication, which is given by infusion (through an IV) every 1–2 weeks in 3–4 week cycles. Depending on which treatment group you are assigned to, you may receive the new medication alone, or combined with one or two other cancer drugs. You will continue treatment as long as the cancer responds and you tolerate the side effects. Throughout the trial, you will have blood tests, scans, and doctor visits to monitor how well the treatment is working and to check for side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States